Mitsubishi UFJ Trust & Banking Corp Cuts Stock Position in Gilead Sciences, Inc. $GILD

Mitsubishi UFJ Trust & Banking Corp decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,318,500 shares of the biopharmaceutical company’s stock after selling 206,767 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Gilead Sciences were worth $146,182,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. EPG Wealth Management LLC lifted its position in shares of Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 89 shares in the last quarter. Southland Equity Partners LLC grew its holdings in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after purchasing an additional 92 shares in the last quarter. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the period. Twelve Points Wealth Management LLC increased its stake in Gilead Sciences by 1.5% during the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after buying an additional 98 shares during the period. Finally, Advantage Trust Co lifted its holdings in Gilead Sciences by 13.6% during the 2nd quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 71,500 shares of company stock valued at $8,336,040. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on GILD. TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Royal Bank Of Canada upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Finally, Citigroup lifted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $128.27.

Gilead Sciences Trading Up 3.7%

Shares of Gilead Sciences stock opened at $122.56 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a fifty day simple moving average of $116.79 and a 200-day simple moving average of $112.48. The stock has a market cap of $152.07 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the business earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.